The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.

Sponsor
Medical University of Warsaw (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05132621
Collaborator
(none)
150
1
25
6

Study Details

Study Description

Brief Summary

The study hypothesis:

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. Its mechanisms are not well understood. It is known that its development is influenced by genetic factors and gender. However, it is believed that in some patients with a specific genetic predisposition, certain environmental factors such as chemicals, including drugs and toxins, smoking, or infections may initiate the development of the disease. Of particular importance seem to be infections, which by stimulating the immune system can induce new symptoms or exacerbate existing ones.

For this reason, links between the microbiome and the clinical course of SLE are being sought. Most available studies concern the intestinal microbiome. So far, the relationship between the genital tract microbiota and the clinical picture of SLE has not been documented.

Aim of the study:

This study aims to identify and differentiate the genital tract microbiota of women with a diagnosis of systemic lupus, IgA nephropathy and a control group of healthy women. The results will be correlated with the clinical presentation of these diseases. In addition, the isolated bacterial strains will be secured for further study.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Smear

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
The Genital Tract Microflora in Women With Systemic Lupus Erythematosus and IgA Nephropathy.
Anticipated Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Participants diagnosed with SLE

Diagnostic Test: Smear
A smear of the posterior vaginal fornix collected with a gynecological speculum.

Participants diagnosed with IgA nephropathy

Diagnostic Test: Smear
A smear of the posterior vaginal fornix collected with a gynecological speculum.

Healthy Participants

Diagnostic Test: Smear
A smear of the posterior vaginal fornix collected with a gynecological speculum.

Outcome Measures

Primary Outcome Measures

  1. Differences in microflora composition between groups of study participants [Two months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Inclusion Criteria:
  • Age >18 years,

  • Confirmed diagnosis of SLE or IgA nephropathy,

  • First half of the menstrual cycle, after the end of bleeding,

  • Signed informed consent to participate in the study.

Exclusion Criteria:
  • Lack of menstruation,

  • Pregnancy,

  • Active infection requiring parenteral or topical antibiotic therapy within 2 weeks before examination,

  • Neoplastic disease of the reproductive tract.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dept. of Immunology, Transplantology and Internal Medicine Transplantation Institute, Warsaw Medical University Warsaw Poland

Sponsors and Collaborators

  • Medical University of Warsaw

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Medical University of Warsaw
ClinicalTrials.gov Identifier:
NCT05132621
Other Study ID Numbers:
  • SLEIGA-1
First Posted:
Nov 24, 2021
Last Update Posted:
Nov 24, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Medical University of Warsaw
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 24, 2021